Liquidia Co. (NASDAQ:LQDA) Insider Rajeev Saggar Sells 2,260 Shares

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Friday, July 19th, Rajeev Saggar sold 1,873 shares of Liquidia stock. The shares were sold at an average price of $11.13, for a total value of $20,846.49.

Liquidia Trading Up 2.2 %

Shares of LQDA stock opened at $11.38 on Wednesday. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99. The company has a market cap of $869.59 million, a P/E ratio of -7.29 and a beta of 0.22. The firm has a fifty day moving average price of $10.40 and a 200 day moving average price of $11.97.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. On average, equities analysts forecast that Liquidia Co. will post -1.69 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. California State Teachers Retirement System lifted its position in Liquidia by 491.2% in the first quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock valued at $681,000 after acquiring an additional 38,369 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after purchasing an additional 125,315 shares during the last quarter. Swiss National Bank acquired a new stake in shares of Liquidia in the 1st quarter valued at about $1,325,000. Boston Partners purchased a new position in Liquidia during the 1st quarter worth approximately $762,000. Finally, Principal Financial Group Inc. increased its position in Liquidia by 112.3% during the first quarter. Principal Financial Group Inc. now owns 36,462 shares of the company’s stock worth $538,000 after buying an additional 19,288 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LQDA has been the subject of several recent research reports. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Oppenheimer initiated coverage on shares of Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating for the company. BTIG Research cut their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Bank of America lowered their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus target price of $24.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).